Shares of CorMedix (CRMD) have gained 35.4% over the past four weeks to close the last trading session at $5.28, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $13 indicates a potential upside of 146.2%.The mean estimate comprises four short-term price targets with a standard deviation of $4.55. While the lowest estimate of $9 indicates a 70.5% increase from the current price l ...

BERKELEY HEIGHTS, N.J., April 08, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ:CRMD), a biopharmaceutical company focused on developing therapeutic products for life-threatening diseases and conditions, today announced that it has entered into a 5-year commercial supply contract with Florida-based dialysis provider, ARC Dialysis, LLC for the supply of DefenCath® (taurolidine and heparin). CorMedix received NDA approval of DefenCath® under the Limited Population Pathway for Antibacterial and Antifungal Dru ...

CorMedix Inc. (NASDAQ:CRMD) Q4 2023 Earnings Conference Call March 12, 2024 8:30 AM ET Company Participants Joe Todisco - Chief Executive Officer Matt David - Executive Vice President, Chief Financial Officer Erin Mistry - Executive Vice President, Chief Commercial Officer Liz Hurlburt - Executive Vice President, Chief Clinical Strategy and Operations Officer Dan Ferry - LifeSci Advisors Conference Call Participants Jason Butler - Citizens JMP Anish Nikhanj - RBC Capital Markets Lew Sulewski - Truist Securi ...

BERKELEY HEIGHTS, N.J., March 12, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening diseases and conditions, today announced financial results for the fourth quarter and full year ended December 31, 2023 and provided an update on its business. Recent Corporate Highlights: On November 15, 2023, CorMedix received FDA approval for its new drug application (NDA) for ...

CORMEDIX INC. REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Berkeley Heights, NJ – March 12, 2024 – CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening diseases and conditions, today announced financial results for the fourth quarter and full year ended December 31, 2023 and provided an update on its business. ● On November 15, 2023, CorMedix re ...

BERKELEY HEIGHTS, N.J., March 06, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases, today announced that it will report its financial results for the fourth quarter and full year ended December 31, 2023, before the market opens on Tuesday, March 12, 2024, and will host a corporate update conference call at 8:30am Eastern Time.  Tuesday, ...

BERKELEY HEIGHTS, N.J., March 06, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases, today announced that it will report its financial results for the fourth quarter and full year ended December 31, 2023, before the market opens on Tuesday, March 12, 2024, and will host a corporate update conference call at 8:30am Eastern Time.  Tuesday, ...

BERKELEY HEIGHTS, N.J., Jan. 30, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening diseases and conditions, today announced updates related to its business and anticipated launch of DefenCath®. Recent Updates: On January 25, 2024 the Center for Medicare & Medicaid Services (CMS) notified CorMedix that the agency has determined DefenCath will be eligible for reim ...

CorMedix Inc. (NASDAQ:CRMD) Q3 2023 Earnings Conference Call November 14, 2023 4:30 PM ET Company Participants Daniel Ferry - LifeSci Advisors Joseph Todisco - CEO Matt David - EVP and CFO Phoebe Mounts - EVP and General Counsel Conference Call Participants Jason Butler - JMP Securities Leszek Sulewski - Truist Securities Gregory Renza - RBC Capital Markets Operator Good afternoon, and welcome to CorMedix Third Quarter 2023 Earnings Conference Call. Today's call is being recorded. [Operator Instructions] At ...

As previously agreed with the FDA, an interim efficacy analysis was performed when the first 28 potential CRBSI cases were identified in our LOCK-IT-100 study that occurred through early December 2017. Based on these first 28 cases, there was a highly statistically significant 72% reduction in CRBSI by DefenCath relative to the active control of heparin (p=0.0034). Because the prespecified level of statistical significance was reached for the primary endpoint and efficacy had been demonstrated with no safet ...